Compare Remitly Global Inc (RELY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs TransMedics Group Inc — how do they compare? Remitly Global Inc trades at $24.13 (market cap $4.98B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Remitly Global Inc is the larger of the two by market cap, and Remitly Global Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and TransMedics Group Inc for 24 Days on average.
| RELY | TMDX | |
|---|---|---|
Market Cap | $4.98B | $2.74B |
Volume | 3,501,150 | 949,331 |
Sector | Technology | Health |
52-Week High | $26.92 | $150.42 |
52-Week Low | $12.20 | $61.99 |
Typical Hold Time | 53 Days | 24 Days |
Enterprise Value | $4.34B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.52, up 2.57% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and achieving profitability with net income of $67.93M. Recent Q2 2026 earnings significantly beat expectations, and positive news highlights partnerships and growth under new leadership.
The outlook is positive, supported by robust revenue growth, expanding profit margins, and a strong analyst consensus. Key risks include execution in a competitive digital payments space and market volatility. With a consensus price target of $30.50, representing significant upside, the stock presents a compelling opportunity for growth-oriented investors, though its current RSI suggests it may be overbought in the short term.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
